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Background
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated 
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-
to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of pona-
tinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome–
positive acute lymphoblastic leukemia (Ph-positive ALL).
Methods
We enrolled 449 heavily pretreated patients who had CML or Ph-positive ALL with re-
sistance to or unacceptable side effects from dasatinib or nilotinib or who had the 
BCR-ABL T315I mutation. Ponatinib was administered at an initial dose of 45 mg 
once daily. The median follow-up was 15 months.
Results
Among 267 patients with chronic-phase CML, 56% had a major cytogenetic response 
(51% of patients with resistance to or unacceptable side effects from dasatinib or 
nilotinib and 70% of patients with the T315I mutation), 46% had a complete cytoge-
netic response (40% and 66% in the two subgroups, respectively), and 34% had a 
major molecular response (27% and 56% in the two subgroups, respectively). Re-
sponses were observed regardless of the baseline BCR-ABL kinase domain mutation 
status and were durable; the estimated rate of a sustained major cytogenetic response 
of at least 12 months was 91%. No single BCR-ABL mutation conferring resistance to 
ponatinib was detected. Among 83 patients with accelerated-phase CML, 55% had a 
major hematologic response and 39% had a major cytogenetic response. Among 62 
patients with blast-phase CML, 31% had a major hematologic response and 23% had 
a major cytogenetic response. Among 32 patients with Ph-positive ALL, 41% had a 
major hematologic response and 47% had a major cytogenetic response. Common 
adverse events were thrombocytopenia (in 37% of patients), rash (in 34%), dry skin (in 
32%), and abdominal pain (in 22%). Serious arterial thrombotic events were observed 
in 9% of patients; these events were considered to be treatment-related in 3%. A total 
of 12% of patients discontinued treatment because of an adverse event.
Conclusions
Ponatinib had significant antileukemic activity across categories of disease stage and 
mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov 
number, NCT01207440.)
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Patients with newly diagnosed chronic myeloid leukemia (CML) frequently receive imatinib. Although initial response 
rates are high, imatinib fails in up to 40% of pa-
tients because of disease resistance, frequently 
because of BCR-ABL kinase domain mutations or 
unacceptable side effects.1,2 Patients who discon-
tinue imatinib may have a response to second-
generation tyrosine kinase inhibitors. However, 
37 to 52% of patients do not have a response,3-8 
and 23 to 26% of patients have an initial major 
cytogenetic response that is lost by 2 years.3,9 The 
prognosis for these patients is very poor. With the 
exception of the small number of patients who are 
candidates for allogeneic stem-cell transplanta-
tion, patients are likely to die from the leukemia.
Ponatinib is a potent oral tyrosine kinase in-
hibitor that is active against unmutated and mu-
tated BCR-ABL, including the threonine-to-iso-
leucine mutation at position 315 (T315I), which 
is present in up to 20% of patients with tyro-
sine kinase inhibitor–resistant disease and con-
fers resistance to all other approved BCR-ABL 
tyrosine kinase inhibitors.10-17 In preclinical ex-
periments, 40 nM of ponatinib (a concentration 
that can be achieved in patients who receive 
daily doses of ≥30 mg18) suppressed the emer-
gence of any single mutation.19 In a phase 1 study, 
ponatinib showed substantial antileukemic ac-
tivity in patients with Philadelphia chromosome 
(Ph)–positive disease who had resistance to or 
unacceptable side effects from previous treatment 
with tyrosine kinase inhibitors.18 Here we de-
scribe the initial results of the phase 2 PACE 
(Ponatinib Ph-positive acute lymphoblastic leu-
kemia [ALL] and CML Evaluation) clinical trial 
of ponatinib in patients who had chronic-phase 
CML, accelerated-phase CML, blast-phase CML, 
or Ph-positive ALL with resistance to or unac-
ceptable side effects from dasatinib or nilotinib 
or with the T315I mutation.
Me thods
Study Oversight
The study was developed jointly by the sponsor, 
Ariad Pharmaceuticals, and the PACE steering com-
mittee (see Appendix A in the Supplementary Ap-
pendix, available with the full text of this article at 
NEJM.org). The protocol (available at NEJM.org) 
was approved by the institutional review board at 
each center. Data were collected with the use of 
the sponsor’s data-management system and were 
analyzed and interpreted by representatives of the 
sponsor in collaboration with the investigators. 
All the authors contributed to and reviewed the 
data reported and vouch for the completeness of 
the data set and the integrity of the analysis. The 
authors also verify that the study was conducted 
in fidelity to the study protocol. All the authors re-
viewed, edited, and approved the final manuscript 
and made the decision to submit the manuscript for 
publication. Professional medical-writing assistance 
was provided by the sponsor.
Patients
Patients were eligible if they were at least 18 years of 
age and had CML or Ph-positive ALL. CML phases 
were defined according to the criteria described 
by Talpaz et al.20 Ph-positive ALL was defined as 
more than 30% lymphoid blasts in blood or bone 
marrow at diagnosis and no history of CML. Ad-
ditional eligibility criteria were resistance to dasa-
tinib or nilotinib (for definitions, see Appendix B 
in the Supplementary Appendix), unacceptable 
side effects of these agents, or development of 
the T315I mutation after any tyrosine kinase in-
hibitor therapy. Patients had to have an Eastern 
Cooperative Oncology Group performance status 
of 2 or lower (on a scale ranging from 0 to 5, 
where 0 indicates that the patient is asymptom-
atic and higher numbers indicate increasing dis-
ability), adequate renal and hepatic function, 
normal pancreatic status, no history of pancre-
atitis, and a normal QT interval corrected with 
the use of Fridericia’s formula. All patients pro-
vided written informed consent.
Study Design and Treatment
This was an open-label, multinational trial in-
volving 66 sites. Patients received an initial dose 
of 45 mg of ponatinib orally once daily. Patients 
were grouped into six cohorts (Fig. S1 in the Sup-
plementary Appendix): patients with chronic-
phase CML with resistance to or unacceptable 
side effects of dasatinib or nilotinib, patients 
with chronic-phase CML and the T315I muta-
tion, patients with accelerated-phase CML with 
resistance to or unacceptable side effects of dasa-
tinib or nilotinib, patients with accelerated-phase 
CML and the T315I mutation, patients with blast-
phase CML or Ph-positive ALL with resistance to 
or unacceptable side effects of dasatinib or ni-
lotinib, and patients with blast-phase CML or Ph-
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positive ALL with the T315I mutation. Assign-
ment to a T315I cohort required confirmation of 
T315I by a central laboratory (MolecularMD) at 
baseline. Treatment was continued until there 
was evidence of disease progression, an adverse 
event occurred that was deemed to necessitate 
treatment cessation, the patient withdrew con-
sent, or the investigator decided to terminate 
treatment.
End Points
The primary end point was a major cytogenetic 
response at any time within the first 12 months 
(in patients with chronic-phase CML) and a major 
hematologic response at any time within the first 
6 months (in patients with accelerated-phase CML, 
blast-phase CML, or Ph-positive ALL). Patients with 
a partial cytogenetic response at enrollment who 
then had a complete cytogenetic response were 
classified as having a major cytogenetic response 
during the trial. Secondary end points for chronic-
phase CML included a complete hematologic re-
sponse (confirmed ≥28 days after the patient first 
met the criteria for a complete hematologic re-
sponse). Secondary end points for accelerated- and 
blast-phase CML and Ph-positive ALL included a 
complete or partial cytogenetic response and a con-
firmed major cytogenetic response. Secondary end 
points for all diagnoses included a major molecu-
lar response, the time to the response, the duration 
of the response, progression-free survival, overall 
survival, and safety. End-point definitions and 
response criteria are described in Appendixes B 
and C, respectively, in the Supplementary Appendix.
Assessments of Efficacy and Safety
Response assessments were performed every 
3 months (in patients with chronic-phase CML) 
or at the end of cycle 1 (for a hematologic and 
cytogenetic response only; 1 cycle was 28 days), 
cycle 2, and every 2 months thereafter (in patients 
with accelerated-phase CML, blast-phase CML, or 
Ph-positive ALL). Molecular response and muta-
tions were assessed by a central laboratory with 
the use of Sanger sequencing (Appendix B in the 
Supplementary Appendix).
We assessed adverse events continuously and 
graded them according to the National Cancer 
Institute Common Terminology Criteria for Ad-
verse Events, version 4.0 (http://evs.nci.nih.gov/ftp1/ 
CTCAE/CTCAE_4.03_2010-06-14_QuickReference 
_8.5x11.pdf). Laboratory evaluations occurred 
weekly during cycle 1, every other week during 
cycles 2 and 3, and monthly thereafter.
Statistical Analysis
The efficacy population included all 444 patients 
who were assigned to a cohort. The safety popu-
lation included all 449 patients who received 1 or 
more doses of ponatinib. The planned sample 
sizes for the cohorts were estimated to rule out 
prespecified null response rates with the use of 
95% confidence intervals as specified in Appen-
dix B in the Supplementary Appendix. Two-sided, 
exact 95% confidence intervals were calculated 
for rates of a major cytogenetic response, major 
hematologic response, complete hematologic re-
sponse, and major molecular response. The dura-
tion of response, progression-free survival, and 
overall survival were estimated with the use of 
the Kaplan–Meier method. Fisher’s exact test was 
used for subgroup comparisons.
R esult s
Patients
From September 2010 to October 2011, we en-
rolled 449 patients: 203 with chronic-phase CML 
and resistance to or unacceptable side effects of 
dasatinib or nilotinib and 64 with chronic-phase 
CML and the T315I mutation, 65 with accelerat-
ed-phase CML and resistance to or unacceptable 
side effects of dasatinib or nilotinib and 18 with 
accelerated-phase CML and the T315I mutation, 
and 48 with blast-phase CML or Ph-positive ALL 
and resistance to or unacceptable side effects of 
dasatinib or nilotinib and 46 with blast-phase 
CML or Ph-positive ALL and the T315I mutation. 
Five patients (3 with chronic-phase CML and 2 with 
accelerated-phase CML) who had a history of the 
T315I mutation were enrolled and treated but 
were not assigned to a cohort because the T315I 
mutation was not confirmed at baseline and the 
patients had not received nilotinib or dasatinib; 
these patients were excluded from the efficacy 
population.
Demographic and baseline characteristics of 
the patients are summarized in Table 1, and in 
Table S1 in the Supplementary Appendix. Thirty-
seven percent of the patients had received two 
tyrosine kinase inhibitors (imatinib, dasatinib, 
nilotinib, or bosutinib), and 55% had received 
three or more. Other previous therapies included 
cytarabine (in 23%) and interferon alfa (in 34%). 
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Among the 427 patients who had previously re-
ceived dasatinib or nilotinib, 88% had resistance 
and 12% had unacceptable side effects. Respons-
es to the most recent nilotinib or dasatinib 
therapy were generally poor (e.g., among pa-
tients with chronic-phase CML, only 26% had 
had a major cytogenetic response and only 3% 
had had a major molecular response) (Table 1). 
Among patients assigned to cohorts with resis-
tance to or unacceptable side effects of these 
agents, BCR-ABL mutations were undetectable in 
67% of patients with chronic-phase CML, 60% of 
patients with accelerated-phase CML, 45% of pa-
tients with blast-phase CML, and 30% of patients 
with Ph-positive ALL. Two or more mutations 
were detectable at baseline in 10% of patients with 
chronic-phase CML, 7% of patients with acceler-
ated-phase CML, 16% of patients with blast-
phase CML, and 28% of patients with Ph-positive 
ALL (Table S2 in the Supplementary Appendix).
At the time of the analysis (November 9, 
2012), the median follow-up was 15 months 
(range, <1 to 25), and 222 patients (49%) were 
still receiving therapy (minimum follow-up, 12 
months) (Table 2). In total, 227 patients (51%) 
discontinued treatment; most of these patients 
had advanced disease. The most common reasons 
for discontinuation were progressive disease (in 
7% of patients with chronic-phase CML and in 
37% of patients with advanced disease) and ad-
verse events (in 13% of patients with chronic-




Among patients with chronic-phase CML, 56% 
(95% confidence interval [CI], 50 to 62) had a 
major cytogenetic response by 12 months, which 
was the primary end point (51% of those with re-
sistance to or unacceptable side effects of dasa-
tinib or nilotinib and 70% of those with the T315I 
mutation). A total of 46% of patients with chronic-
phase CML had a complete cytogenetic response 
(40% of those with resistance to or unacceptable 
side effects of dasa tinib or nilotinib and 66% of 
those with the T315I mutation), and 34% had a 
major molecular response (27% of those with re-
sistance to or unacceptable side effects of dasa-
tinib or nilotinib and 56% of those with the 
T315I mutation). A deeper molecular response (i.e., 
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or less [with the ratio expressed as a percentage 
on the International Scale],  referred to as a mo-
lecular response 4.5) was  observed in 15% of 
patients with chronic-phase CML (12% of those 
with resistance to or unacceptable side effects 
of dasatinib or nilotinib and 23% of those with 
the T315I mutation (Fig. 1A, and Table S3 in the 
Supplementary Appendix).
The median time to a major cytogenetic re-
sponse in patients who had a response was 
2.8 months (range, 1.6 to 11.3), and the duration 
ranged from 1 day to 19.4 months or more (the 
median was not reached). Among patients who 
had a major cytogenetic response, the estimated 
rate of a sustained response of at least 12 months 
was 91% (95% CI, 85 to 95) (Fig. 1A). Rates of 















Continued to receive treatment 
— no. (%)
171 (63) 45 (53) 5 (8) 1 (3) 222 (49)
Discontinued treatment — no. (%)*
Had progressive disease 20 (7) 18 (21) 31 (50) 17 (53) 86 (19)
Had adverse event† 35 (13) 9 (11) 10 (16) 2 (6) 56 (12)
Died‡ 5 (2) 2 (2) 6 (10) 5 (16) 18 (4)
Withdrew consent 14 (5) 0 3 (5) 1 (3) 18 (4)
Had other reasons§ 5 (2) 6 (7) 6 (10) 1 (3) 18 (4)
Lack of efficacy 11 (4) 3 (4) 0 4 (12) 18 (4)
Physician’s decision 8 (3) 2 (2) 1 (2) 1 (3) 12 (3)
Noncompliance 1 (<1) 0 0 0 1 (<1)
Median follow-up (range) — mo 15 (0.1–25) 16 (3.6–25) 6 (0.1–21) 6 (0.1–19) 15 (0.1–25)
* The primary reasons for discontinuation are listed.
† Adverse events leading to discontinuation in more than 1 patient were thrombocytopenia in 18 patients (4.0%), myelo-
dysplastic syndrome in 2 (0.4%), sepsis in 2 (0.4%), pneumonia in 2 (0.4%), cerebral infarction in 2 (0.4%), and cardiac 
failure in 2 (0.4%).
‡ Five deaths were assessed by the investigators as being possibly or probably related to ponatinib: one patient with 
chronic-phase CML had pneumonia and one patient with chronic-phase CML had an acute myocardial infarction, one 
patient with accelerated-phase CML had fungal pneumonia, one patient with blast-phase CML had a gastric hemorrhage, 
and one patient with Ph-positive ALL had a cardiac arrest. Other reasons for death were: sepsis or septic shock (in four 
patients), cardiac arrest (in two patients), congestive cardiac failure (in two patients), cardiopulmonary failure (in one  patient), 
dehydration (in one patient), the hyperviscosity syndrome (in one patient), neoplasm progression (in one  patient), and 
small intestinal obstruction (in one patient).
§ This category includes transplantation (in five patients with chronic-phase CML, five with accelerated-phase CML, six 
with blast-phase CML, and one with Ph-positive ALL).
Figure 1 (facing page). Response to Ponatinib According to Type of Leukemia, Resistance to or Unacceptable Side Effects from Previous 
Treatment with Dasatinib or Nilotinib, and T3151 Mutation Status.
Panel A shows the percentages of patients with chronic-phase CML who had a complete hematologic response, major cytogenetic response, 
complete cytogenetic response, or major molecular response. It was estimated that 91% (95% confidence interval [CI], 85 to 95) of the 
patients with a major cytogenetic response would have a sustained response of at least 12 months. Overall survival was estimated to be 
94% at 12 months. Panel B shows the percentages of the patients with accelerated-phase CML who had a major hematologic response, 
major cytogenetic response, complete cytogenetic response, or major molecular response. It was estimated that 48% (95% CI, 32 to 63) 
of the patients with a major hematologic response would have a sustained response of at least 12 months. Overall survival was estimated 
to be 84% at 12 months. Panel C shows the percentages of patients with blast-phase CML who had a major hematologic response, major 
cytogenetic response, or complete cytogenetic response. It was estimated that 42% (95% CI, 19 to 63) of the patients with a major hema-
tologic response would have a sustained response of at least 12 months. Overall survival was estimated to be 29% at 12 months (median, 
7 months). Panel D shows the percentages of patients with Ph-positive ALL who had a major hematologic response, major cytogenetic 
response, or complete cytogenetic response. It was estimated that 8% (95% CI, 0.5 to 29) of the patients with a major hematologic re-
sponse would have a sustained response of at least 12 months. Overall survival was estimated to be 40% at 12 months (median, 8 months).
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Ponatinib in Ph-Positive Leukemias

















    













r   
















    













r   











































0 6 12 18 24


























































r   














r   
















    













r   









































0 6 12 18 24

























































r   














r   
















    









































0 6 12 18 24

























































r   














r   
















    









































0 6 12 18 24






































































The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;19 nejm.org november 7, 20131790
progression-free and overall survival (Fig. 1A) 
were estimated to be 80% and 94%, respectively, 
at 12 months. Three patients with chronic-phase 
CML had progression to accelerated-phase CML 
or blast-phase CML; accelerated-phase CML de-
veloped in two additional patients with a history 
of this condition.
Prespecified subgroup analyses were con-
ducted to evaluate the effect of clinical factors 
on response rates. Patients who received fewer 
previous tyrosine kinase inhibitors, were younger, 
and had a shorter interval between diagnosis and 
enrollment in the study tended to have higher 
response rates (Table 3, and Table S4 in the 
Supplementary Appendix). Despite the higher 
response rates observed in the T315I cohorts as 
compared with the cohorts with resistance to or 
unacceptable side effects of dasatinib or niloti nib, 
a post hoc multivariate analysis indicated that 
T315I was not a significant predictor of a major 
cytogenetic response. Other features, especially 
higher dose intensity and younger age in patients 
with the T315I mutation (Table S5 in the Supple-
mentary Appendix), explain the higher response 
rates.21 High response rates were observed among 
patients with chronic-phase CML regardless of 
mutation status (Table S6 in the Supplementary 
Appendix), and responses were observed for each 
of the 15 mutations present in more than one 
patient at baseline (Table S7 in the Supplementary 
Appendix). At the time of the analysis, six patients 
had an unsustained major cytogenetic response 
and discontinued treatment; end-of-treatment 
samples were available for four of these patients. 
No change in BCR-ABL mutation status was ob-
served in these patients (Appendix D in the Supple-
mentary Appendix). No single BCR-ABL mutation 
conferring resistance to ponatinib was observed 
(Appendix D in the Supplementary Appendix).
Accelerated-Phase CML
Among patients with accelerated-phase CML, 
55% (95% CI, 44 to 66) had a major hematologic 
response by 6 months (the primary end point). 
A major cytogenetic response was seen in 39%, 
24% had a complete cytogenetic response, and 
16% had a major molecular response (Fig. 1B, 
and Table S3 in the Supplementary Appendix).
The median time to a major hematologic re-
sponse was 3 weeks (range, 2 to 25), and the 
duration ranged from 1 month to 21 months or 
more (median, 12 months); the estimated rate of a 
sustained response of at least 12 months was 48% 
(Fig. 1B). The median time to a major cytogenetic 
response was 3.7 months (range, 0.8 to 9.7), 
and the estimated rate of a sustained response 
of at least 12 months was 73%. The rate of 
progression-free survival was estimated to be 55% 
at 12 months (median, 18 months), and the rate of 
overall survival (Fig. 1B) was estimated to be 
84% at 12 months.
Like the patients with chronic-phase CML, the 
patients with accelerated-phase CML who received 
fewer previous tyrosine kinase inhibitors tended 
to have higher response rates (Table S8 in the 
Supplementary Appendix). High response rates 
were observed among patients with BCR-ABL mu-
tations, including those with the T315I mutation, 
and among those without BCR-ABL mutations 
(Table S6 in the Supplementary Appendix), and no 
single mutation conferring resistance to ponati-
nib was observed (Appendix D in the Supple-
mentary Appendix).
Blast-Phase CML and Ph-Positive ALL
Among patients with blast-phase CML, 31% 
(95% CI, 20 to 44) had a major hematologic re-
sponse by 6 months (the primary end point), 
23% had a major cytogenetic response, and 18% 
had a complete cytogenetic response (Fig. 1C). 
Table S9 in the Supplementary Appendix shows 
outcomes in patients with myeloid blast-phase 
CML and those with lymphoid blast-phase CML. 
Among patients with Ph-positive ALL, 41% 
(95% CI, 24 to 59) had a major hematologic re-
sponse, 47% had a major cytogenetic response, 
and 38% had a complete cytogenetic response 
(Fig. 1D). 
The median time to a major hematologic re-
sponse in patients with blast-phase CML who had 
a response was 4.1 weeks (range, 1.7 to 16.1), the 
duration ranged from 1 month to 20 months or 
more (median, 5 months), and the estimated rate 
of a sustained response of at least 12 months was 
42% (Fig. 1C). The median time to a major hema-
tologic response in patients with Ph-positive 
ALL was 2.9 weeks (range, 1.6 to 24), the dura-
tion was 2 months to 14 months or more (me-
dian, 3 months), and the estimated rate of a sus-
tained response of at least 12 months was 8% 
(Fig. 1D). The median time to a major cytoge-
netic response in patients with blast-phase CML 
who had a response was 1.9 months (range, 0.9 
to 5.5), and the estimated rate of a sustained 
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response of at least 12 months was 66%. The 
median time to a major cytogenetic response 
in patients with Ph-positive ALL was 1 month 
(range, 0.9 to 3.7), the median duration was 
3.7 months, and the estimated rate of a sus-
tained response of at least 12 months was 32%. 
Among patients with blast-phase CML, the rate 
of progression-free survival at 12 months was 
estimated to be 19% (median, 4 months), and 
among patients with Ph-positive ALL, the rate of 
progression-free survival was estimated to be 
7% (median, 3 months). The overall survival rate 
at 12 months was estimated to be 29% (median, 
7 months) among patients with blast-phase CML 
and 40% (median, 8 months) among patients 
with Ph-positive ALL (Fig. 1C and 1D). No single 
mutation was associated with resistance to 
ponatinib. However, the acquisition of com-
pound mutations (≥2 mutations in the same 
BCR-ABL allele) was sometimes observed in pa-
tients with an unsustained major hematologic 
response; all these patients had one of the muta-
tions at study entry (Appendix D in the Supple-
mentary Appendix).
Safety
The median duration of ponatinib treatment was 
12.8 months (range, 1 day to >24.8 months). The 
median relative dose intensity (the proportion of 
administered doses relative to planned doses) 
was 0.84. Dose reductions occurred in 55% of the 
patients (median time to dose reduction, 2.3 
months; range, 1 day to 19 months), and 67% of 
the patients had at least one dose interruption.
The most common nonhematologic adverse 
events that were considered by the site investigator 
to be at least possibly related to treatment were 
rash (in 34% of the patients), dry skin (in 32%), 
and abdominal pain (in 22%). These events were 
primarily grade 1 or 2 in severity (Table 4, and 
Table S10 in the Supplementary Appendix, which 
lists events in each of the six study cohorts). The 
Table 3. Response According to Previous Therapy in Patients with Chronic-Phase CML.
Variable All Patients
Patients with  
Resistance  
or Unacceptable 
Side Effects T315I Mutation
no. % (95% CI) no. % (95% CI) no. % (95% CI)
One previous approved tyrosine kinase inhibitor* 19† 4 12
Major cytogenetic response‡ 79 (54–94) 50 (7–93) 83 (52–98)
Complete cytogenetic response 74 (49–91) 50 (7–93) 75 (43–95)
Major molecular response 47 (24–71) 0 67 (35–90)
Two previous approved tyrosine kinase inhibitors* 98 68 30
Major cytogenetic response‡ 67 (57–76) 63 (51–75) 77 (58–90)
Complete cytogenetic response 56 (46–66) 49 (36–61) 73 (54–88)
Major molecular response 36 (26–46) 28 (18–40) 53 (34–72)
Three previous approved tyrosine kinase inhibitors* 141 119 22
Major cytogenetic response‡ 45 (37–54) 44 (35–53) 55 (32–76)
Complete cytogenetic response 39 (31–48) 37 (28–46) 50 (28–72)
Major molecular response 33 (26–42) 29 (21–38) 55 (32–76)
Four previous approved tyrosine kinase inhibitors* 12 12
Major cytogenetic response‡ 58 (28–85) 58 (28–85) —
Complete cytogenetic response 25 (5–57) 25 (5–57) —
Major molecular response 8 (0.2–38) 8 (0.2–38) —
* Patients may have received other, nonapproved tyrosine kinase inhibitors.
† This category includes the three patients who were not assigned to a cohort; they were T315I-negative at baseline and 
had not previously received dasatinib or nilotinib, but they had received imatinib.
‡ A major cytogenic response consists of a partial cytogenic response plus a complete cytogenic response.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;19 nejm.org november 7, 20131792
most common hematologic adverse events were 
thrombocytopenia (in 37% of patients), neutro-
penia (in 19%), and anemia (in 13%) (Table 4).
Nonhematologic serious adverse events that oc-
curred in at least 1% of patients were pancreatitis 
(in 5%), abdominal pain (in 2%), increased lipase 
levels (in 2%), diarrhea (in 1%), pyrexia (in 1%), 
and myocardial infarction (in 1%). Hematologic 
serious adverse events that occurred in at least 
1% of patients were thrombocytopenia (in 2%), 
anemia (in 1%), neutropenia (in 1%), febrile neutro-
penia (in 1%), and pancytopenia (in 1%). Eighteen 
patients died during the study. The most com-
mon cause of death was sepsis or septic shock 
in four patients (one patient with accelerated-
phase CML, one with blast-phase CML, and two 
with Ph-positive ALL). Five deaths were attribut-
able to ponatinib (Table 2).
























Grade 3  
or 4
number of patients (percent)
Nonhematologic events
Rash† 107 (40) 10 (4) 25 (29) 3 (4) 15 (24) 2 (3) 6 (19) 1 (3)
Dry skin 104 (39) 5 (2) 21 (25) 1 (1) 10 (16) 1 (2) 7 (22) 0
Abdominal pain 74 (27) 20 (7) 15 (18) 4 (5) 6 (10) 1 (2) 6 (19) 2 (6)
Headache 63 (23) 5 (2) 10 (12) 0 7 (11) 1 (2) 4 (12) 0
Increased lipase 57 (21) 27 (10) 12 (14) 11 (13) 8 (13) 7 (11) 3 (9) 2 (6)
Fatigue 51 (19) 4 (1) 17 (20) 1 (1) 7 (11) 2 (3) 3 (9) 0
Constipation 53 (20) 3 (1) 11 (13) 1 (1) 3 (5) 0 6 (19) 1 (3)
Myalgia 46 (17) 3 (1) 16 (19) 0 7 (11) 0 2 (6) 0
Arthralgia 45 (17) 6 (2) 16 (19) 1 (1) 8 (13) 0 1 (3) 0
Nausea 38 (14) 1 (<1) 9 (11) 0 12 (19) 0 1 (3) 0
Increased alanine aminotransferase 31 (11) 9 (3) 10 (12) 2 (2) 5 (8) 2 (3) 1 (3) 1 (3)
Pancreatitis 19 (7) 17 (6) 7 (8) 5 (6) 3 (5) 2 (3) 0 0
Hypertension 25 (9) 6 (2) 6 (7) 3 (4) 1 (2) 1 (2) 1 (3) 1 (3)
Increased aspartate aminotransferase 24 (9) 5 (2) 8 (9) 3 (4) 4 (6) 1 (2) 1 (3) 1 (3)
Increased blood amylase 16 (6) 4 (1) 6 (7) 3 (4) 3 (5) 2 (3) 1 (3) 0
Increased γ-glutamyltransferase 11 (4) 4 (1) 7 (8) 2 (2) 2 (3) 1 (2) 0 0
Dyspnea 13 (5) 4 (1) 6 (7) 0 4 (6) 1 (2) 0 0
Cardiac failure 3 (1) 2 (<1) 1 (1) 1 (1) 2 (3) 2 (3) 0 0
Hematologic events
Thrombocytopenia 111 (41) 86 (32) 36 (42) 28 (33) 17 (27) 16 (26) 3 (9) 2 (6)
Neutropenia 44 (16) 38 (14) 22 (26) 22 (26) 14 (23) 11 (18) 4 (12) 4 (12)
Anemia 27 (10) 15 (6) 14 (16) 8 (9) 14 (23) 13 (21) 5 (16) 4 (12)
Decreased white-cell count 11 (4) 7 (3) 7 (8) 5 (6) 0 0 1 (3) 1 (3)
Pancytopenia 2 (1) 2 (1) 3 (4) 2 (2) 3 (5) 3 (5) 0 0
Febrile neutropenia 1 (<1) 1 (<1) 2 (2) 2 (2) 2 (3) 2 (3) 2 (6) 2 (6)
* Treatment-related adverse events were defined as events that the site investigators deemed to have a possible, probable, or definite relation-
ship to ponatinib. Listed are the treatment-related adverse events that were reported in at least 10% of the patients, along with any incidence 
of grade 3 or 4 events in more than 1% of the total study population.
† Rash includes erythematous and papular rash.
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Thrombocytopenia, the most common adverse 
event, usually occurred early in the course of treat-
ment (within the first 3 months). Pancreatitis, the 
most common serious adverse event, tended to 
occur early (median time to first onset, 14 days; 
69% of cases occurred in the first month and 17% 
of cases occurred in the second month) and was 
reversible (most cases resolved within 1 week). All 
29 patients with pancreatitis resumed treatment 
with ponatinib, and 3 patients had recurrent 
events (multiple events occurred in 1 patient). 
Only 1 patient (with chronic-phase CML) discon-
tinued treatment because of pancreatitis. Clini-
cal management of thrombocytopenia and pan-
creatitis was consistent with protocol-stipulated 
dose modifications (Appendix B in the Supple-
mentary Appendix).
Arterial thrombotic events were observed. 
Cardiovascular, cerebrovascular, and peripheral 
vascular events that were considered by the site 
investigator to be at least possibly related to 
treatment were observed in 2.2%, 0.7%, and 1.6% 
of patients, respectively. Regardless of the rela-
tionship of the events to treatment, as ascribed 
by the investigators, 7.1% of patients had cardio-
vascular events, 3.6% had cerebrovascular events, 
and 4.9% had peripheral vascular events. Two 
patients discontinued ponatinib after the occur-
rence of one event. Of the remaining patients, 
36% had one or more additional events. Cardio-
vascular, cerebrovascular, and peripheral vascu-
lar serious adverse events that were related to 
treatment were observed in 2.0%, 0.4%, and 0.4% 
of patients, respectively. Regardless of the rela-
tionship to treatment, 5.1% of the patients had 
cardiovascular serious adverse events, 2.4% had 
cerebrovascular serious adverse events, and 2.0% 
had peripheral vascular serious adverse events. 
Fifty-five percent of these patients had a history 
of ischemic disease at study enrollment, and 
95% had one or more risk factors (hypertension, 
diabetes, hypercholesterolemia, or obesity) with 
or without a history of ischemic disease, non-
ischemic cardiac disease, or venous thrombo-
embolism.
Discussion
Many patients with a new diagnosis of Ph-positive 
leukemia have a prolonged clinical benefit from 
targeted therapy with imatinib or second-genera-
tion drugs.2,14,22,23 However, resistance to therapy 
eventually develops in many patients. Once avail-
able treatment options are exhausted, the prog-
nosis is poor.24
Response rates to previous therapy, a major 
predictor of response to subsequent therapy,25 
provide reasonable estimates of expected responses 
to the best available therapy. In this study, ponati-
nib was associated with robust antileukemic 
activity in heavily pretreated patients with CML 
or Ph-positive ALL, and the response rates were 
substantially higher than those reported for the 
most recent course of nilotinib or dasatinib 
treatment received before the study treatment.
At concentrations that are “clinically achiev-
able” (i.e., blood concentrations of 40 nM of 
ponatinib observed in patients who receive daily 
doses of ≥30 mg), ponatinib has shown pre-
clinical activity against all BCR-ABL mutants 
tested and has uniformly suppressed the emer-
gence of single-mutant clones in a muta genesis 
assay.19 In this trial, among patients with chron-
ic-phase CML, responses were observed against 
all mutants present in more than 1 patient. 
Among patients in whom the response was not 
sustained, end-of-treatment analyses did not reveal 
the emergence of single mutations. Compound 
mutations developed in 21 patients, primarily 
those with blast-phase CML or Ph-positive ALL 
who entered the study with one or more muta-
tions, mainly T315I. In particular, the development 
of E255K/T315I, E255V/F317I, or T315I/F359V 
compound mutations was observed in more than 
1 patient (Appendix D in the Supplementary Ap-
pendix). This is consistent with the genetic in-
stability associated with advanced disease,26,27 
and it is also consistent with preclinical data 
showing emergence of certain compound muta-
tions on a background of T315I or E255V single 
mutations at concentrations of ponatinib that are 
clinically achievable.19 Compound mutations in 
BCR-ABL may develop sequentially and have 
been associated with resistance to other tyrosine 
kinase inhibitors.28-31 Data from this study, 
together with the phase 1 data,18 did not show a 
single mutation conferring resistance to pona-
tinib. We speculate that the use of ponatinib at 
earlier stages of disease could prevent the emer-
gence of resistance caused by mutations. Mecha-
nisms of resistance to ponatinib in the absence 
of mutations remain to be identified.
Response rates were high among patients 
with chronic-phase CML who did not have de-
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tectable BCR-ABL mutations, as well as among 
patients with mutations other than T315I. Re-
sponse rates were higher among patients with 
T315I, which is resistant to all other targeted 
therapies. However, a multivariate analysis 
showed that the presence of T315I itself is not a 
predictor of response; rather, the differences in 
response rates are explained by the clinical fea-
tures of these patients. Younger, less heavily 
pretreated patients were able to receive higher 
doses of ponatinib without unacceptable adverse 
effects and had higher response rates, irrespective 
of their T315I mutation status.21 Since responses 
were observed regardless of the presence or ab-
sence and type of mutations, mutation analysis 
might not be necessary in every case. Certainly, 
a patient can be properly treated with ponatinib 
without undergoing prior mutation testing, if it 
is not available. However, knowledge of any mu-
tations present at the start of therapy, as a base-
line, may be useful for recognizing the emer-
gence of preexisting mutations or of compound 
mutations that might lead to ponatinib resis-
tance. Thus, mutation analysis is still important 
for the treatment of patients with CML.32,33
Response rates in our study tended to be 
higher among patients treated with fewer previ-
ous tyrosine kinase inhibitors. Among patients 
with chronic-phase CML who received one previ-
ous tyrosine kinase inhibitor, 15 of 19 (79%) had 
a major cytogenetic response, whereas 66 of 98 
(67%) had a major cytogenetic response after 
two previous tyrosine kinase inhibitors. In stud-
ies involving patients with resistance to or side 
effects of imatinib who were treated with niloti-
nib, dasatinib, or bosutinib, the reported major 
cytogenetic response rates were 48 to 63%.3-8 
Few data are available on the activity of second-
generation tyrosine kinase inhibitors in patients 
who had treatment failure with imatinib and 
either nilotinib or dasatinib, but patients with 
chronic-phase CML have been reported to have 
major cytogenetic response rates ranging from 32 
to 50%, with a limited duration of response.34-37
In our study, serious-grade arterial thrombotic 
events (including cardiovascular, cerebrovascular, 
and peripheral vascular events) were seen in only 
8.9% of the patients who received ponatinib 
(treatment-related events, 2.9%). However, the 
United States Prescribing Information (USPI) for 
ponatinib recently included a boxed warning for 
arterial thrombotic events. The rates of these 
events that were initially reported in the USPI in 
December 2012 were 7.6% for serious adverse 
events and 11.4% for all adverse events, serious 
or not (median duration of exposure, 11 months 
among all patients in the trial). Data on an ad-
ditional 13 months of exposure in patients who 
continued in the trial, which were available after 
submission and acceptance of our manuscript, 
showed that the cumulative incidence of serious 
arterial thrombotic events was 11.8%; the inci-
dence of all arterial thrombotic events, serious or 
not, was 17.1%. When longer patient exposure is 
taken into account, the rates of these events per 
unit of time have not changed with time. How-
ever, the accumulation of adverse events has 
prompted a partial clinical hold on ongoing trials 
of ponatinib and the termination by the sponsor 
of the frontline randomized trial of ponatinib 
versus imatinib (Ponatinib in Newly Diagnosed 
Chronic Myeloid Leukemia [CML] [EPIC]). Aware-
ness of these ponatinib-associated events is criti-
cal in the treatment of patients who are receiving 
ponatinib. In this study, arterial thrombotic 
events were observed predominantly in patients 
with either a documented ischemic condition or 
one or more risk factors at baseline. Patients with 
these clinical features should be carefully moni-
tored. More data are needed to determine the 
cardiovascular risk attributable to ponatinib and 
the mechanism of action underlying these events.
It is also important to investigate whether inter-
ventions, such as the use of aspirin or other 
drugs that inhibit platelet aggregation, may re-
duce the risk of these events. However, pona-
tinib has been reported to have a mild inhibitory 
effect on platelet aggregation.38 Cardiovascular 
adverse events have also been observed in pa-
tients treated with other BCR-ABL–targeted tyro-
sine kinase inhibitors, including peripheral arte-
rial occlusive disease in patients treated with 
nilotinib.39-41
In conclusion, ponatinib showed clinically sig-
nificant activity in patients with CML and those 
with Ph-positive ALL.
Supported by Ariad Pharmaceuticals and by grants (CA016672 
and CA049639) to the M.D. Anderson Cancer Center from the 
National Institutes of Health, grants from the National Institute 
for Health Research Biomedical Research Centre (to Drs. Apperley 
and Goldman), and Leukemia and Lymphoma Society Scholar in 
Clinical Research Awards (to Drs. Deininger and Shah).
Dr. Cortes reports receiving consulting fees from Ariad Phar-
maceuticals, Pfizer, and Teva and grant support from Ariad 
Pharmaceuticals, Bristol-Myers Squibb, Novartis, Pfizer, and Teva; 
Dr. Kim, receiving lecture fees from Novartis, Bristol-Myers Squibb, 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Ponatinib in Ph-Positive Leukemias
n engl j med 369;19 nejm.org november 7, 2013 1795
and Ilyang and grant support from Ariad Pharmaceuticals, No-
vartis, Bristol-Myers Squibb, Ilyang, and Pfizer; Dr. Pinilla-Ibarz, 
receiving consulting and lecture fees from Ariad Pharmaceuticals, 
Novartis, Bristol-Myers Squibb, Pfizer, and Teva; Dr. le Coutre, 
receiving lecture fees from Novartis, Bristol-Myers Squibb, and 
Pfizer and grant support from Novartis; Dr. Paquette, receiving 
consulting and lecture fees from Ariad Pharmaceuticals; Dr. Chuah, 
receiving lecture fees from Bristol-Myers Squibb and Novartis 
and having a pending patent on an East Asian polymorphism in 
the BIM gene that predicts resistance to targeted cancer therapy; 
Dr. Nicolini, receiving consulting fees from Pfizer, Teva, Novartis, 
and Bristol-Myers Squibb and grant support from Novartis and 
Bristol-Myers Squibb; Dr. Apperley, receiving consulting and lecture 
fees from Novartis, Bristol-Myers Squibb, and Pfizer; Dr. Talpaz, 
receiving consulting and lecture fees from Ariad Pharmaceuticals, 
Novartis, and Bristol-Myers Squibb and grant support from Ariad 
Pharmaceuticals; Dr. DeAngelo, receiving consulting fees from 
Ariad Pharmaceuticals; Dr. Rea, receiving consulting and lecture 
fees from Ariad Pharmaceuticals, Bristol-Myers Squibb, Novartis, 
Teva, and Pfizer; Dr. Baccarani, receiving consulting and lecture 
fees from Ariad Pharmaceuticals, Novartis, Bristol-Myers Squibb, 
and Pfizer; Dr. Müller, receiving consulting fees from Novartis, 
Bristol-Myers Squibb, and Ariad Pharmaceuticals and grant sup-
port from Novartis and Bristol-Myers Squibb; Dr. Gambacorti-
Passerini, receiving personal fees from Bristol-Myers Squibb 
and grant support from Pfizer; Dr. Wong, holding stock in 
 MolecularMD; Drs. Lustgarten, Rivera, Clackson, Turner, and 
Haluska being employees of and holding stock in Ariad Pharma-
ceuticals; Dr. Guilhot, receiving lecture fees from Ariad Pharmaceu-
ticals; Dr. Deininger, receiving consulting fees from Bristol-Myers 
Squibb, Ariad Pharmaceuticals, and Novartis and grant sup-
port from Bristol-Myers Squibb, Novartis, Celgene, and Gilead; 
Dr. Hoch haus, receiving grant support from Ariad Pharmaceuticals, 
Novartis, Bristol-Myers Squibb, Pfizer, and Merck Sharp & Dohme; 
Dr. Hughes, receiving consulting fees, lecture fees, and grant sup-
port from Novartis, Bristol-Myers Squibb, and Ariad Pharmaceu-
ticals; and Dr. Shah, receiving consulting fees and grant support 
from Ariad Pharmaceuticals and Bristol-Myers Squibb. No other 
potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients, their caregivers, the site investigators 
and research personnel for their participation in the trial; the 
members of the Ponatinib Ph+ ALL and CML Evaluation Study 
Team (Ariad Pharmaceuticals); and Holly Maier, Ph.D., of Ariad 
Pharmaceuticals for medical-writing assistance.
appendix
The authors’ full names and academic degrees are as follows: Jorge E. Cortes, M.D., Dong-Wook Kim, M.D., Ph.D., Javier Pinilla-Ibarz, 
M.D., Ph.D., Philipp le Coutre, M.D., Ronald Paquette, M.D., Charles Chuah, M.D., Franck E. Nicolini, M.D., Ph.D., Jane F. Apperley, 
M.D., Hanna J. Khoury, M.D., Moshe Talpaz, M.D., John DiPersio, M.D., Ph.D., Daniel J. DeAngelo, M.D., Ph.D., Elisabetta Abruzzese, 
M.D., Ph.D., Delphine Rea, M.D., Ph.D., Michele Baccarani, M.D., Martin C. Müller, M.D., Carlo Gambacorti-Passerini, M.D., Ste-
phane Wong, Ph.D., Stephanie Lustgarten, Ph.D., Victor M. Rivera, Ph.D., Tim Clackson, Ph.D., Christopher D. Turner, M.D., Frank 
G. Haluska, M.D., Ph.D., François Guilhot, M.D., Michael W. Deininger, M.D., Ph.D., Andreas Hochhaus, M.D., Timothy Hughes, 
M.D., John M. Goldman, D.M., Neil P. Shah, M.D., Ph.D., and Hagop Kantarjian, M.D.
The authors’ affiliations are as follows: the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (J.E.C., 
H.K.); Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.); H. Lee Moffitt Cancer Center, Tampa, FL 
(J.P.-I.); Charité–Universitätsmedizin Berlin, Berlin (P.C.), III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim (M.C.M.), 
and Abteilung Hämatologie und Onkologie, Universitätsklinikum Jena, Jena (A.H.) — all in Germany; Ronald Reagan UCLA Medical 
Center, University of California, Los Angeles (R.P.); Singapore General Hospital, Duke–National University of Singapore Graduate Medical 
School, Singapore (C.C.); Centre Hospitalier Lyon Sud, Pierre Bénite (F.E.N.), Service des Maladies du Sang and Clinical Investigation 
Center (CIC), Hôpital Saint-Louis, Paris (D.R.), and INSERM CIC, Centre Hospitaliere Universitaire de Poitiers, Poi tiers (F.G.) all in 
France; Centre for Haematology, Imperial College London, London (J.F.A., J.M.G.); Winship Cancer Institute of Emory University, At-
lanta (H.J.K.); Comprehensive Cancer Center, University of Michigan, Ann Arbor (M.T.); Washington University School of Medicine, St. 
Louis (J.D.); Dana–Farber Cancer Institute, Boston (D.J.D.); Hematology, S. Eugenio Hospital, Tor Vergata University, Rome (E.A.), the 
Department of Hematology and Oncology L. and A. Seragnoli, S. Orsola–Malpighi University Hospital, Bologna (M.B.), and Unità di Ri-
cerca Clinica–Ematologia, Azi enda Ospedaliera San Gerardo/University of Milano Bicocca, Monza (C.G.-P.) — all in Italy; MolecularMD, 
Portland, OR (S.W.); Ariad Pharmaceuticals, Cambridge, MA (S.L., V.M.R., T.C., C.D.T., F.G.H.); Huntsman Cancer Institute, Univer-
sity of Utah, Salt Lake City (M.W.D.); Institute of Medicine and Veterinary Science, Adelaide, SA, Australia (T.H.); and University of 
California San Francisco, San Francisco (N.P.S.).
References
1. Deininger M, O’Brien SG, Guilhot F, 
et al. International randomized study of 
interferon vs STI571 (IRIS) 8-year follow-
up: sustained survival and low risk for pro-
gression or events in patients with newly 
diagnosed chronic myeloid leukemia in 
chronic phase (CML-CP) treated with ima-
tinib. Blood 2009;114:Suppl:1126. abstract.
2. Hochhaus A, O’Brien SG, Guilhot F, et 
al. Six-year follow-up of patients receiving 
imatinib for the first-line treatment of 
chronic myeloid leukemia. Leukemia 2009; 
23:1054-61. [Erratum, Leukemia 2010;24: 
1102.]
3. Cortes JE, Kantarjian HM, Brümmen-
dorf TH, et al. Safety and efficacy of 
 bosutinib (SKI-606) in chronic phase 
Philadelphia chromosome-positive chronic 
myeloid leukemia patients with resistance 
or intolerance to imatinib. Blood 2011;118: 
4567-76.
4. Shah NP, Cortes JE, Schiffer CA, et al. 
Four-year follow-up of patients with 
chronic-phase chronic myeloid leukemia 
(CP-CML) receiving 100 mg of dasatinib 
once daily. J Clin Oncol 2010;28:Suppl: 
6512. abstract.
5. Sprycel (dasatinib) tablet for oral use: 
prescribing information. Princeton, NJ: 
Bristol-Myers Squibb, October 2011.
6. Tasigna (nilotinib) capsules: prescrib-
ing information. East Hanover, NJ: Novartis, 
October 2011.
7. Kantarjian HM, Giles F, Gattermann N, 
et al. Nilotinib (formerly AMN107), a highly 
selective BCR-ABL tyrosine kinase inhibitor, 
is effective in patients with Philadelphia 
chromosome-positive chronic myelogenous 
leukemia in chronic phase following imati-
nib resistance and intolerance. Blood 2007; 
110:3540-6.
8. Shah NP, Kantarjian HM, Kim DW, 
et al. Intermittent target inhibition with 
dasatinib 100 mg once daily preserves 
 efficacy and improves tolerability in ima-
tinib-resistant and -intolerant chronic-
phase chronic myeloid leukemia. J Clin 
Oncol 2008;26:3204-12.
9. Kantarjian HM, Giles FJ, Bhalla KN, 
et al. Nilotinib is effective in patients with 
chronic myeloid leukemia in chronic phase 
after imatinib resistance or intolerance: 
24-month follow-up results. Blood 2011; 
117:1141-5.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
n engl j med 369;19 nejm.org november 7, 20131796
Ponatinib in Ph-Positive Leukemias
10. Cortes J, Jabbour E, Kantarjian H, et 
al. Dynamics of BCR-ABL kinase domain 
mutations in chronic myeloid leukemia 
after sequential treatment with multiple 
tyrosine kinase inhibitors. Blood 2007;110: 
4005-11.
11. Nicolini FE, Corm S, Lê QH, et al. 
 Mutation status and clinical outcome of 
89 imatinib mesylate-resistant chronic 
myelogenous leukemia patients: a retro-
spective analysis from the French Inter-
group of CML. Leukemia 2006;20:1061-6.
12. Jabbour E, Kantarjian HM, Jones D, et 
al. Characteristics and outcome of chron-
ic myeloid leukemia patients with F317L 
BCR-ABL kinase domain mutation after 
therapy with tyrosine kinase inhibitors. 
Blood 2008;112:4839-42.
13. Soverini S, Colarossi S, Gnani A, et al. 
Contribution of ABL kinase domain mu-
tations to imatinib resistance in different 
subsets of Philadelphia-positive patients: 
by the GIMEMA Working Party on Chronic 
Myeloid Leukemia. Clin Cancer Res 2006; 
12:7374-9.
14. Kantarjian HM, Shah NP, Cortes JE, 
et al. Dasatinib or imatinib in newly di-
agnosed chronic-phase chronic myeloid 
leukemia: 2-year follow-up from a ran-
domized phase 3 trial (DASISION). Blood 
2012;119:1123-9.
15. Kantarjian HM, Finn IW, Goldberg SL, 
et al. Nilotinib vs imatinib in patients with 
newly diagnosed chronic myeloid leuke-
mia in chronic phase (CML-CP): ENESTnd 
3-year follow-up. J Clin Oncol 2012;30: 
Suppl:6509. abstract.
16. O’Hare T, Eide CA, Deininger MW. 
Bcr-Abl kinase domain mutations, drug re-
sistance, and the road to a cure for chronic 
myeloid leukemia. Blood 2007;110:2242-9.
17. Kim S-H, Menon H, Jootar S, et al. 
Efficacy and safety of radotinib in chron-
ic phase chronic myeloid leukemia pa-
tients with resistance or intolerance to 
BCR-ABL tyrosine kinase inhibitors: ra-
dotinib phase 2 clinical trial. Blood 2012; 
120:Suppl:695. abstract.
18. Cortes JE, Kantarjian H, Shah NP, et 
al. Ponatinib in refractory Philadelphia 
chromosome–positive leukemias. N Engl 
J Med 2012;367:2075-88.
19. O’Hare T, Shakespeare WC, Zhu X, et 
al. AP24534, a pan-BCR-ABL inhibitor for 
chronic myeloid leukemia, potently in-
hibits the T315I mutant and overcomes 
mutation-based resistance. Cancer Cell 
2009;16:401-12.
20. Talpaz M, Shah NP, Kantarjian H, et 
al. Dasatinib in imatinib-resistant Phila-
delphia chromosome–positive leukemias. 
N Engl J Med 2006;354:2531-41.
21. Mauro MJ, Cortes JE, Kim DW, et al. 
Multivariate analyses of the clinical and 
molecular parameters associated with ef-
ficacy and safety in patients with chronic 
myeloid leukemia (CML) and Philadelphia 
chromosome-positive acute lymphoblastic 
leukemia (Ph+ ALL) treated with ponati-
nib in the PACE trial. Blood 2012;120: 
Suppl:3747. abstract.
22. Kantarjian HM, Hochhaus A, Saglio 
G, et al. Nilotinib versus imatinib for the 
treatment of patients with newly diag-
nosed chronic phase, Philadelphia chro-
mosome-positive, chronic myeloid leu-
kaemia: 24-month minimum follow-up 
of the phase 3 randomised ENESTnd trial. 
Lancet Oncol 2011;12:841-51. [Erratum, 
Lancet Oncol 2011;12:989.]
23. Cortes JE, Kim DW, Kantarjian HM, et 
al. Bosutinib versus imatinib in newly di-
agnosed chronic-phase chronic myeloid 
leukemia: results from the BELA trial. 
J Clin Oncol 2012;30:3486-92.
24. Kantarjian H, O’Brien S, Talpaz M, et 
al. Outcome of patients with Philadelphia 
chromosome-positive chronic myelogenous 
leukemia post-imatinib mesylate failure. 
Cancer 2007;109:1556-60.
25. Jabbour E, Kantarjian H, O’Brien S, et 
al. Predictive factors for outcome and re-
sponse in patients treated with second-
generation tyrosine kinase inhibitors for 
chronic myeloid leukemia in chronic phase 
after imatinib failure. Blood 2011;117: 
1822-7.
26. Johansson B, Fioretos T, Mitelman F. 
Cytogenetic and molecular genetic evolu-
tion of chronic myeloid leukemia. Acta 
Haematol 2002;107:76-94.
27. Calabretta B, Perrotti D. The biology of 
CML blast crisis. Blood 2004;103:4010-22.
28. Bauer RC, Sänger J, Peschel C, Duyster J, 
von Bubnoff N. Sequential inhibitor ther-
apy in CML: in vitro simulation elucidates 
the pattern of resistance mutations after 
second- and third-line treatment. Clin Can-
cer Res 2013;19:2962-72.
29. Shah NP, Skaggs BJ, Branford S, et al. 
Sequential ABL kinase inhibitor therapy 
selects for compound drug-resistant BCR-
ABL mutations with altered oncogenic 
potency. J Clin Invest 2007;117:2562-9.
30. Khorashad JS, Kelley TW, Szankasi P, 
et al. BCR-ABL1 compound mutations in 
tyrosine kinase inhibitor-resistant CML: 
frequency and clonal relationships. Blood 
2013;121:489-98.
31. Soverini S, De Benedittis C, Machova 
Polakova K, et al. Unraveling the complex-
ity of tyrosine kinase inhibitor-resistant 
populations by ultra-deep sequencing of 
the BCR-ABL kinase domain. Blood 2013; 
122:1634-48.
32. National Comprehensive Cancer Net-
work. NCCN clinical practice guidelines in 
oncology: chronic myelogenous leuke-
mia, version 4.2013 (http://www.nccn.org/
professionals/physician_gls/pdf/cml.pdf).
33. Baccarani M, Deininger MW, Rosti G, 
et al. European LeukemiaNet recommen-
dations for the management of chronic 
myeloid leukemia: 2013. Blood 2013;122: 
872-84.
34. Garg RJ, Kantarjian H, O’Brien S, et 
al. The use of nilotinib or dasatinib after 
failure to 2 prior tyrosine kinase inhibi-
tors: long-term follow-up. Blood 2009;114: 
4361-8.
35. Giles FJ, Abruzzese E, Rosti G, et al. 
Nilotinib is active in chronic and acceler-
ated phase chronic myeloid leukemia fol-
lowing failure of imatinib and dasatinib 
therapy. Leukemia 2010;24:1299-301.
36. Ibrahim AR, Paliompeis C, Bua M, et 
al. Efficacy of tyrosine kinase inhibitors 
(TKIs) as third-line therapy in patients 
with chronic myeloid leukemia in chronic 
phase who have failed 2 prior lines of TKI 
therapy. Blood 2010;116:5497-500.
37. Khoury HJ, Cortes JE, Kantarjian HM, 
et al. Bosutinib is active in chronic phase 
chronic myeloid leukemia after imatinib 
and dasatinib and/or nilotinib therapy 
failure. Blood 2012;119:3403-12.
38. Neelakantan P, Marin D, Laffan M, 
Goldman J, Apperley J, Milojkovic D. Plate-
let dysfunction associated with ponatinib, 
a new pan BCR-ABL inhibitor with efficacy 
for chronic myeloid leukemia resistant to 
multiple tyrosine kinase inhibitor therapy. 
Haematologica 2012;97:1444.
39. Kim TD, Rea D, Schwarz M, et al. 
 Peripheral artery occlusive disease in 
chronic phase chronic myeloid leukemia 
patients treated with nilotinib or imati-
nib. Leukemia 2013;27:1316-21.
40. Giles FJ, Mauro MJ, Hong F, et al. 
Rates of peripheral arterial occlusive dis-
ease in patients with chronic myeloid leu-
kemia in the chronic phase treated with 
imatinib, nilotinib, or non-tyrosine kinase 
therapy: a retrospective cohort analysis. 
Leukemia 2013;27:1310-5.
41. Xu Z, Cang S, Yang T, Liu D. Cardio-
toxicity of tyrosine kinase inhibitors in 
chronic myelogenous leukemia therapy. 
Hematol Rev 2009;1:17-21.
Copyright © 2013 Massachusetts Medical Society.
journal archive at nejm.org
Every article published by the Journal is now available at NEJM.org, beginning  
with the first article published in January 1812. The entire archive is fully searchable, 
and browsing of titles and tables of contents is easy and available to all.  
Individual subscribers are entitled to free 24-hour access to 50 archive articles per year. 
Access to content in the archive is available on a per-article basis and is also  
being provided through many institutional subscriptions.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
